Head of IT Laboratory Services, EU/APAC Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of
the research-driven pharmaceutical company Boehringer Ingelheim. The
focus in doing so is on diseases for which no satisfactory treatment
option exists to date. The company therefore concentrates on developing
innovative therapies that can extend patients’ lives. In animal health,
Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim
is one of the pharmaceutical industry’s top 20 companies. Some 50,000
employees create value through innovation daily for the three business
areas human pharmaceuticals, animal health and biopharmaceuticals. In
2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion
euros. R&D expenditure, exceeding three billion euros, corresponded
to 17.0 per cent of net sales.
Check out the incredible speaker line-up to see who will be joining Karlheinz.